Loading
TB-Bs1 is a bispecific antibody from Traverse Biotech that links T cells to tumour cells carrying ROR2, being developed for solid tumours.
TB-Bs1 is the lead product on the pipeline page of Traverse Biotech: a CD3 by ROR2 bispecific antibody made on the DuoBody platform, for ROR2-positive solid tumours. The company cites published work on ROR2 as a cancer target. No clinical trial is registered.
Described by the company as a CD3 by ROR2 DuoBody bispecific antibody: one arm binds CD3 on T cells and the other ROR2 on tumour cells, bringing the two together. Connects to CD3.
1.One arm of TB-Bs1 binds CD3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TB-Bs1" OR ABSTRACT:"TB-Bs1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TB-Bs1, not a curated reading list.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/